Amarin   Report issue

Contributed to NME For profit Phase 4
Founded: Ballsbridge Ireland (1991)

Organization Overview

First Clinical Trial
2005
NCT00146211
First Marketed Drug
1991
medroxyprogesterone (provera)
First NDA Approval
2012
icosapent ethyl (vascepa)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Amarin Corporation | Amarin Neuroscience Ltd | Amarin Pharma Inc. | AMARIN PHARMS

Active Ingredients

Marketed Drugs (2)

icosapent ethyl (vascepa) (2012 NDA)

medroxyprogesterone (provera) (1974)

Drugs in Phase 4 Trials (1)

icosapent ethyl (vascepa) (9 trials)

Indications

Approved Indications


 

Hypertriglyceridemia

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Colonic Neoplasms (Phase 3)

Dyslipidemias (Phase 1)

Huntington Disease (Phase 3)

Hypertriglyceridemia (Phase 3)

Lipid Metabolism Disorders (Phase 1)

Liver Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Respiratory Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 1